Public-domain · open source
OpenJurist
← 413 F.3d 1361 - Seachange International, Inc. v. C-COR Inc.

Seachange International, Inc. v. C-COR Inc.’s Empirical Analysis

413 F.3d 1361 · 2005

Citation profile

141
cited by 141 later decisions
1
states following
May 2025
most recently cited

34 federal appellate · 30 district · 1 state decisions

How this case has been cited

Cited by 141 later decisions — most recently May 2025 · most notably PharmaStem Therapeutics, Inc. v. Viacell, Inc. (2007), Purdue Pharma Lp Pf Sa v. Endo Pharmaceuticals Inc (2006)

34 federal appellate · 30 district · 1 state decisions

820200520102020decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Relationships

Applies 28 U.S.C. § 1295 · 35 U.S.C. § 102 · 35 U.S.C. § 103

Relies on Cybor Corporation v. Fas Technologies, Inc., and Fastar Ltd., Defendants-Cross · Cardinal Chemical Company v. Morton International Inc · Teleflex, Inc. v. Ficosa North America Corp. · Pitney Bowes, Inc. v. Hewlett-Packard Co. · Scimed Life Systems, Inc. v. Advanced Cardiovascular Systems, Inc.

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 141 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “Where an applicant argues that a claim possesses a feature that the prior art does not possess in order to overcome a prior art rejection, the argument may serve to narrow the scope of otherwise broad claim language.”
    3 later decisions quote this exact passage · from the majority
  2. “Claim differentiation is a guide, not .a rigid rule.”). While the doctrine of claim differentiation creates a presumption that a limitation included in a dependent claim is not also recited in the claim from which that claim depends, that presumption is overcome in this instance by the weight of the intrinsic evidence. . During the Markman hearing, counsel for Sprint also characterized this statement as defining”
    1 later decision quote this exact passage · from the majority
  3. “constitutes a public record of the patentee's representations concerning the scope and meaning of the claims, and competitors are entitled to rely on those representations when ascertaining the degree of lawful conduct, such as designing around the claimed invention.”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.